{"id":"NCT01687712","sponsor":"Fertility Biotech AG","briefTitle":"Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF","officialTitle":"Phase III Investigator and Assessor Blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF) in Normal Ovulatory Women 35 to 42 Years Old Undergoing in Vitro Fertilization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-25","primaryCompletion":"2015-09-10","completion":"2016-11-14","firstPosted":"2012-09-19","resultsPosted":"2017-10-18","lastUpdate":"2017-12-05"},"enrollment":1100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Infertility"],"interventions":[{"type":"DRUG","name":"AFOLIA","otherNames":["Follitropin-alfa"]},{"type":"DRUG","name":"Gonal-f® RFF","otherNames":["Follitropin-alfa"]}],"arms":[{"label":"AFOLIA","type":"EXPERIMENTAL"},{"label":"Gonal-f® RFF","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to show that AFOLIA, a recombinant manufactured human follicle stimulating hormone (r-hFSH) has a similar efficacy and safety profile compared to Gonal-f® RFF.","primaryOutcome":{"measure":"Clinical Pregnancy Rate After One Cycle of Treatment - ITT Population","timeFrame":"Six weeks post embryo transfer","effectByArm":[{"arm":"AFOLIA","deltaMin":114,"sd":null},{"arm":"Gonal-f® RFF","deltaMin":138,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"35 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":19},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":549},"commonTop":["Headache","Procedural pain","Injection site erythema","Abortion early","Nausea"]}}